had been introduced. "AstraZeneca's tactics in marketing its cholesterol-lowering drug, rosuvastatin, raise disturbing questions about how drugs enter clinical practice problems with crestor what problems with crestor exist to protect patients from inadequately investigated medicines," according to his editorial. The Lancet's editorial.

The Lancet, criticised the way Crestor had been problems with crestor "AstraZeneca's tactics in marketing its cholesterol-lowering drug, rosuvastatin, raise disturbing problems with crestor about how drugs enter clinical practice and what measures exist to protect patients from problems with crestor investigated medicines," according to his editorial. The Lancet's editorial position is that the risk [of rhabdomyolysis] is greater with Crestor than with other marketed statins", but has problems with crestor that a warning about this side effect, as well as a kidney toxicity warning, be added to the product label.[7][edit] Notes^ a b Nissen SE, Nicholls SJ, Sipahi I, et al (2006). "Effect of very high-intensity statin therapy on regression of problems with crestor atherosclerosis: the ASTEROID problems with crestor (PDF). JAMA 295 (13): 1556-65. doi:10.1001/jama.295.13.jpc60002. PMID 16533939.^ "FDA problems with crestor New Drug for Lowering Cholesterol", The Food and Drug Administration (March 14, 2005). Retrieved on 2005-03-20. - This page is subject to change; the date reflects problems with crestor last.

McCormick A, Schneck D, Smith G, Warwick M (2001). "Preclinical and clinical pharmacology problems with crestor Rosuvastatin, a new.